NewcelX (formerly NLS Pharma)

What NewcelX (formerly NLS Pharma) does

NewcelX Ltd. is a clinical-stage biopharmaceutical company developing regenerative cell therapies and small-molecule drugs for Type 1 Diabetes, amyotrophic lateral sclerosis (ALS), and a range of central nervous system (CNS) disorders. The company was formed in October 2025 through the merger of NLS Pharmaceutics Ltd. (Switzerland, founded 2015) and Kadimastem Ltd. (Israel), and trades on the Nasdaq Capital Market under the ticker NCEL from a headquarters in Kloten, Switzerland, with research operations in Nes Ziona, Israel. It employs 11-50 people and addresses patient populations with severe unmet need, including insulin-dependent Type 1 Diabetes patients seeking a functional cure, ALS patients with rapidly progressive fatal disease, and individuals with narcolepsy or other CNS disorders.

The company's core technology is a proprietary human pluripotent stem cell (hPSC) platform that enables scalable cell expansion and precise differentiation into therapeutic cell types. Its lead program, IsletRx, is a stem-cell-derived insulin-producing islet therapy for Type 1 Diabetes, combined with proprietary micro-encapsulation technology designed to protect transplanted cells from host immune attack without chronic immunosuppression. AstroRx is a fully differentiated human astrocyte therapy for ALS that has completed a Phase I/2a trial in Israel and received FDA IND clearance for a US Phase IIa multi-site trial. The DOXA platform is a discovery-stage small-molecule program targeting orexin receptors (OX1R/OX2R), sigma-1 receptor, cathepsins, SGLT2, and adiponectin receptors for CNS and metabolic indications. Supporting partnerships include Eledon Pharmaceuticals (NCEL-101 for Type 1 Diabetes), iTolerance (ITOL-102 with iTOL100 microgel), TargetGene (gene-edited cell therapies), and Aexon Labs (AEX-6xx CNS series), with scientific advisory ties to Barrow Neurological Institute, Hadassah Medical Center, and the University of Miami Diabetes Research Institute.

Commercially, NewcelX is pre-revenue. The company funds operations through equity capital markets rather than product sales, with a cumulative funding history of multiple small private placements and a $25 million committed equity facility. Revenue is expected to materialize only upon successful clinical development and regulatory approval of pipeline assets, with future commercialization planned through specialty pharmacy and healthcare provider channels. The working revenue model consists of one-time licensing of cell therapy and small-molecule products, supplemented by licensing royalties and potential co-development partnerships; current revenue model descriptions include both pharmaceutical product sales and licensing/partnership revenue streams. No commercial pricing is publicly disclosed because no products are on market.

Name

NewcelX (formerly NLS Pharma)

Legal name

NewcelX Ltd.

Website

https://nlspharma.com

Company type

Public

Founded year

2015

Headcount range

11–50 employees

Short description

NewcelX is a clinical-stage biopharmaceutical company developing stem cell-derived therapies and small-molecule drugs for Type 1 Diabetes, ALS, and CNS disorders, leveraging a proprietary human pluripotent stem cell platform.

Ownership category

akta.pro rank

Headquarters

HQ city

Stans

HQ country

Switzerland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Sales: Long-term revenue expected from commercialization of cell therapy products (IsletRx for Type 1 Diabetes, AstroRx for ALS) and small-molecule drugs (DOXA platform) upon successful clinical development and regulatory approval
2. Licensing and Partnership Revenue: Potential licensing deals and co-development partnerships for pipeline programs including DOXA platform and gene-edited cell therapies

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

NewcelX develops clinical-stage regenerative cell therapies and small-molecule drug candidates derived from a proprietary human pluripotent stem cell (hPSC) platform. Its lead product IsletRx is a stem-cell-derived pancreatic islet cell therapy for Type 1 Diabetes using micro-encapsulation for immune protection; AstroRx® is an astrocyte cell therapy for ALS with completed Phase I/2a and FDA IND clearance; and the DOXA platform is a multi-target small-molecule discovery program addressing orexin, cathepsin, and metabolic pathways for CNS disorders.

Product overview

NewcelX is a clinical-stage biopharmaceutical company that offers a platform of cell therapy and small-molecule products. The core portfolio includes: IsletRx (lead stem-cell-derived islet replacement therapy for Type 1 Diabetes), AstroRx® (cell therapy for ALS with completed Phase 1/2a trial), and DOXA (discovery-stage orexin-targeting small-molecule platform for CNS disorders). The company leverages human pluripotent stem cell technology for scalable cell expansion and differentiation, with proprietary micro-encapsulation for immune protection. The company was founded in 2025 through the merger of NLS Pharmaceutics Ltd. and Kadimastem Ltd.

Differentiator

Problem solved

Functional benefit

Products and services

• IsletRx Stem-cell-derived islet cell therapy for insulin-dependent Type 1 Diabetes, designed to restore insulin production using human pluripotent stem cell-derived insulin-secreting pancreatic islet cells combined with proprietary micro-encapsulation technology that protects the cells from the host immune system without requiring chronic immunosuppressive drugs.
• AstroRx Cell therapy product using fully differentiated human healthy astrocytes derived from human embryonic stem cells via proprietary suspension culture technology, administered by intrathecal injection into spinal cord fluid to support and protect motor neurons in patients with amyotrophic lateral sclerosis (ALS).
• DOXA Platform Multi-target small-molecule discovery platform targeting orexin receptors (OX1R/OX2R), sigma-1 receptor, cathepsin inhibition (CTSS/CTSL), SGLT2 modulation, and adiponectin receptor activation to address narcolepsy, excessive daytime sleepiness, ALS, diabetes-related complications, and broader CNS and metabolic disorders.
• IsletRxPlus (ITOL-102) Stem-cell-derived pancreatic islet cell therapy co-developed with iTolerance Inc., combining IsletRxPlus cells with iTOL100 microgel to provide local immune tolerance for cell therapy without requiring chronic immunosuppression, aimed at providing a functional cure for Type 1 Diabetes.
• DOXA-Islet Combination Therapy Holistic combination therapy approach that leverages the DOXA small-molecule platform's metabolic regulation enhancement together with IsletRx stem-cell-derived islet transplantation to provide comprehensive diabetes management and disease modification.

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered core, expansion and strategic.

• Eledon PharmaceuticalscoreStrategic or Co-development Partner · 1 April 2026Collaboration with Eledon Pharmaceuticals for development of NCEL-101 Type 1 Diabetes therapy. Eledon provides expertise and support for stem cell-based islet replacement therapy development as part of NewcelX's lead diabetes program. Funding of $1.35 million private placement combined with $25 million equity facility to advance the program.
• Aexon LabsexpansionStrategic or Co-development Partner · 30 October 2025Partnership to expand CNS drug development platform with AEX-6xx series, a new class of small molecules targeting arousal stability, cognition, and neuroprotection. Companies plan to initiate preclinical trials and explore co-development opportunities for sleep and neurodegenerative disease treatments.
• TargetGene BiotechnologiesstrategicTechnology or Integration · 27 October 2025Strategic collaboration via Memorandum of Understanding with TargetGene to develop next-generation gene-edited cell therapies. Collaboration combines Kadimastem's cell therapy platforms with TargetGene's advanced gene-editing technology to enhance treatment efficacy for ALS and diabetes.
• iTolerance Inc.coreStrategic or Co-development PartnerCollaboration on ITOL-102 diabetes program combining NewcelX's IsletRxPlus cells with iTOL100 microgel to provide local immune tolerance for cell therapy without chronic immunosuppression. The ITOL-102 program aims to develop a stem-cell-derived pancreatic islet cell therapy that could cure Type 1 Diabetes without lifelong immunosuppression.
• Barrow Neurological InstitutestrategicStrategic or Co-development PartnerStrategic advisory relationship with Prof. Jeremy Shefner, Chief Medical Officer at Barrow Neurological Institute, providing guidance on ALS clinical development and AstroRx program. Barrow is internationally recognized leader in neurological diseases with one of largest multidisciplinary brain and spine programs in US.
• Hadassah Medical Center / Hadassah BrainLabsstrategicStrategic or Co-development PartnerCollaboration with Prof. Tamir Ben-Hur, Associate Director of Hadassah BrainLabs, who joined Scientific Advisory Board. Prof. Ben-Hur leads Department of Neurology at Hadassah and focuses on cell therapy for neurological diseases including MS, with over 100 scientific publications.
• University of Miami Miller School of Medicine / Diabetes Research InstitutestrategicStrategic or Co-development PartnerCollaboration with Dr. Camillo Ricordi, Director Emeritus of Diabetes Research Institute at University of Miami. Dr. Ricordi serves as Steering Committee Co-Chair for Vertex stem cell-derived islet transplant program (VX-880) and advancing first-in-human trial with iTolerance.

Scale indicators14 records

Recent moves8 records

Expansion highlights16 records

Direct peers

• Clene Nanomedicine: Clene develops novel therapeutics for neurodegenerative diseases including ALS, with a focus on catalytically active gold nanocrystals. Directly comparable to NewcelX's AstroRx ALS program in indication and clinical-stage positioning.
• Vertex Pharmaceuticals: Vertex is developing VX-880, a stem cell-derived islet cell therapy for Type 1 Diabetes that directly competes with NewcelX's IsletRx. Vertex has the same key scientific collaborator (Camillo Ricordi) and is further advanced clinically, making it the most direct comparator in the T1D cell therapy space.
• BrainStorm Cell Therapeutics: BrainStorm's NurOwn is an autologous cell therapy for ALS — directly comparable to NewcelX's AstroRx astrocyte therapy in indication, mechanism (cell-based neuroprotection), and clinical stage. Both target an unmet need in ALS with cell-based approaches.
• ViaCyte: ViaCyte (acquired by Vertex) develops stem cell-derived islet cell therapies for Type 1 Diabetes with encapsulation-based immune-evasion strategies. Its PEC-Direct and VC-02 programs are direct predecessors/competitors to NewcelX's IsletRx and IsletRxPlus (ITOL-102) approaches.
• Alector: Alector develops neurodegenerative disease therapeutics using genetically validated targets and immune-neurology approaches for ALS, FTD, and Alzheimer's. Comparable to NewcelX as a clinical-stage CNS/neurodegeneration biotech with a similar investor profile and Nasdaq listing.
• CRISPR Therapeutics: CRISPR Therapeutics is a clinical-stage gene-editing company with programs in hemoglobinopathies and oncology, and is a logical peer for NewcelX's gene-edited cell therapy collaboration with TargetGene. Both operate at the intersection of cell therapy and gene editing for serious diseases.
• Sangamo Therapeutics: Sangamo is a clinical-stage genomic medicine company developing cell and gene therapies, including autologous cell therapy programs for CNS and metabolic indications. Highly comparable in stage, technology platform nature, and Nasdaq micro-cap profile.
• BioXcel Therapeutics: BioXcel is a clinical-stage CNS-focused biopharma developing small-molecule therapies for neuropsychiatric and neurodegenerative conditions via AI-enabled drug re-positioning. Comparable to NewcelX's DOXA discovery-stage multi-target CNS platform and similar Nasdaq-listed micro-cap profile.

Broad incumbents

• Eli Lilly: Eli Lilly is a major incumbent in both diabetes (insulin franchises, Mounjaro/Zepbound) and CNS therapeutics. While not a direct cell-therapy competitor, it sets the strategic backdrop and partnership/licensing benchmark for any company pursuing functional cures in these indications.

Emerging players

• Axsome Therapeutics: Axsome develops novel CNS therapeutics for narcolepsy, depression, and migraine. Comparable to NewcelX's DOXA program targeting narcolepsy and excessive daytime sleepiness via orexin pathway modulation, making it a relevant peer for the small-molecule CNS franchise.

Market position

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

• Xx.com/NLSPharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds14 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NewcelX (formerly NLS Pharma)